Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATL-RIC
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
ATL-RIC is a multi-drug reduced-intensity conditioning (RIC) regimen developed by the National Cancer Institute (NCI) for patients with peripheral T-cell lymphoma (PTCL) or adult T-cell leukemia/lymphoma (ATL) undergoing allogeneic hematopoietic cell transplantation. The regimen is designed to provide potent lymphodepletion and cytoreduction while minimizing transplant-related toxicity. It consists of equine anti-thymocyte globulin (e-ATG), pentostatin, low-dose cyclophosphamide, busulfan, filgrastim, ruxolitinib, and zidovudine. This combination targets T-cells, DNA replication, JAK/STAT signaling, and viral reverse transcription, providing a comprehensive preparatory environment for stem cell engraftment in aggressive T-cell malignancies.
- Other names
- ATL-RIC conditioning regimen
02
Targets
CD2 (T-cell Surface Antigen CD2)IL2RA (Interleukin-2 receptor alpha subunit)CD3 (T-cell surface glycoprotein CD3)CD4 (T lymphocyte surface antigen)CD44 (CD44 antigen)PTPRC (Receptor-type tyrosine-protein phosphatase C)CD8A (CD8 alpha/beta Coreceptor)HLA-DR (Human leukocyte antigen DR)ITGAL (Integrin alpha L (CD11a))ITGB2 (Complement receptor 4)MHC I (MHC class I})ITGB1 (Integrin beta-1)MR1 (Thioesterase PNKD)CD86 (T-lymphocyte activation antigen CD86)ADA (Adenosine deaminase)N7-G (DNA guanine-N7 adduct)DNACSF3R (Granulocyte colony-stimulating factor receptor)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on ATL-RIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATL-RIC.